Voveran

Rediff.com » News » Voveran

News for Voveran

Business
Sports

NPPA slaps Rs 300-crore penalty on Novartis

Drug major Novartis has been slapped with a Rs 300-crore (Rs 3 billion) penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine. The Swiss......

Markets end higher; Sep inflation, RIL Q2 eyed

Benchmark share indices staged a recovery in late trades, amid firm European cues, helped by a rebound in financials while IT shares gained post upbeat July-September earnings from Infosys. The......

Old is gold: Heritage pharma brands take the lead

At a time when pharmaceutical companies are investing billions of dollars to develop new and path-breaking medicines, it is the old and heritage brands that continue to dominate the market. Sales......

Novartis may revise open offer price

Switzerland-based, Novartis AG, the parent company of Novartis India, is likely to revise its open offer price to buy back an additional stake of up to 39 per cent of equity to increase its......

Pharma firms bank on brand extensions

Stiff competition in a highly fragmented market has led the domestic drug makers to depend on brand extensions rather than new product launches to corner a market share. A market intelligence......

I did not take any stimulant but was on painkillers: Malik

IMAGE: Wrestler Sumit Malik had secured the 125kg category quota for the Tokyo Olympic during the qualifying tournament in Sofia, Bulgaria, last month but was handed suspension for failing his......

Rediff News

Voveran

News for Voveran

NPPA slaps Rs 300-crore penalty on Novartis

Markets end higher; Sep inflation, RIL Q2 eyed

Old is gold: Heritage pharma brands take the lead

Novartis may revise open offer price

Pharma firms bank on brand extensions

I did not take any stimulant but was on painkillers: Malik

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS